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Conclusions: New experimental data have been obtained at 
the ARRONAX cyclotron that permits to expand the 
knowledge of the tin-117m TTY up to 65 MeV. The results of 
the TALYS 1.6 code, which reproduce correctly the tin-117m 
production cross section, have been used to determine the 
tin-117m SA taking into account the stables and long live tin 
isotopes produced during the irradiation. The highest tin-
117m SA could be obtained using 40 MeV alpha beams which 
gives a TTY of 3.9 MBq/(µA.h). It is possible to get higher 
production yields but with a lower SA of the final product. 
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Purpose: Terbium is an element of growing interest for 
medical applications, considered as the “Swiss-knife of 
nuclear medicine” [1]. Indeed, four terbium radioisotopes 
can be used in nuclear medicine. Tb-149 is considered for 
alpha targeted therapy, Tb-161 for beta- targeted therapy, 
Tb-152 for Positron Emission Tomography (PET) and Tb-155 
for Single Photon Emission Computed Tomography (SPECT). 
However, terbium-155 can also be used as a radionuclide that 
emits Auger electrons for therapy. The interest on this 
radioisotope is increased by the conversion electrons emitted 
and the possibility to follow the treatment by SPECT imaging 
in a theranostic approach. The Tb-155 production has been 
investigated using the deuteron beam delivered by the 
ARRONAX cyclotron [2] and natural gadolinium target, 
motivated by the lack of data for this reaction at the 
beginning of our experiments. 
Materials/methods: Tb-155 production study has been 
considered at the ARRONAX cyclotron (France) taking 
advantage of the deuteron beam ranging from 15 to 35 MeV. 
Production cross section measurements of Tb-155 as well as 
radioactive contaminants have been made using the stacked-
foils technique. The stacks were made of thin natural 
gadolinium as targets, aluminum foils as degraders and thin 
natural titanium as monitor foils. After irradiation, the 
activity of each radionuclides produced in the foils has been 
determined by γ spectrometry [3]. From the cross section 
values obtained during these experiments, the Tb-155 Thick 
Target production Yield (TTY) has been calculated and 
compared with the other Tb-155 production routes using data 
available in the literature. When no experimental data were 
available, the TALYS code [4] version 1.6 helped to estimate 
the TTY. 
Results: In 2014, cross section values have been published for 
the Gd-nat(d,x)Tb-155 reaction [5]. Our set of data is in good 
agreement therewith. Tb-155 production cross section values 
for the Gd-nat(p,x) and Gd-nat(α,x) are also available in the 
literature. The Tb-155 TTY have been compared for each 
routes. Close values are obtained for the proton and the 
deuteron route. The Gd-nat(α,x) reaction gives the lowest 
TTY, whatever the incident beam energy. However, the use 
of a natural gadolinium target leads to the production of 
several contaminants and especially of Tb-156g which has the 
same half-life as Tb-155. Results based on calculations for 
two reactions using Gd-154 and Gd-155 enriched targets 
with, respectively, deuterons and protons as projectiles, are 
also discussed [3,6]. The Tb-159(p,5n)Dy-155(ε)Tb-155 
reaction, with results published in 2014 [7], is also discussed 
as a promising production route using high energy protons. 
Conclusions: New experimental data have been obtained at 
the ARRONAX cyclotron for the Gd-nat(d,x) reaction with a 
special emphasis on the Tb-155 production. The results have 
been compared with different production routes, using 
natural and enriched gadolinium target. Based on the 
calculations published in 2012 [6], the Gd-155(p,n) reaction 
seems to be the most promising for the production of Tb-155 
with gadolinium as target element. However, the Tb-
159(p,5n)Dy155(ε)Tb155 seems an interesting alternative. 
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Purpose: In this study, we report the rapid arc commissioning 
and dosimetric verification measurements performed with 
the electronic portal imaging device (EPID) having portal 
dosimetry software. 
Material and Methods: The dosimetric tests were performed 
on RapidArc capable Varian Unique linac, which is equipped 
with millennium 120 Dynamic Multi Leaf Collimators (DMLCs) 
and having 6 MV X-ray beam. The Varian RapidArc QA files, 
Eclipse treatment planning system (TPS) and EPID portal 
dosimetry system were used in this study. The RapidArc QA 
files incorporate following tests. 1) DMLC dosimetry. 2) 
Picket Fence (PF) test vs. gantry angle. 3) PF test during 
